The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence

Journal of Drugs in Dermatology, May-June, 2005 by Aditya K. Gupta, Jennifer E. Ryder, Lindsay E. Lynch, Amir Tavakkol

20. Velthuis PJ, Nijenhuis M. Treatment of onychomycosis with terbinafine in patients with Down's syndrome. Br J Dermatol. 1995;133:144-146.

21. Smith EB, et al. Clinical trial: the safety of terbinafine in patients over the age of 60 years: a multicenter trial in onychomycosis of the feet. Int J Dermatol. 2000;39:861-864.

22. Gupta AK, et al. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. J Am Acad Dermatol. 2001;44:479-484.

23. Lee KH, et al. Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients. Transplant Proc. 1996;28:1488-1489.

24. Gupta AK, et al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol. 2000;39:746-753.

25. Gupta AK, et al. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada--a multicenter survey of 2001 patients. Int J Dermatol. 1997;36:783-787.

26. Conant MA. The AIDS epidemic. J Am Acad Dermatol. 1994;31:S47-S50.

27. Aly R, Berger T. Common superficial fungal infections in patients with AIDS. Clin Infect Dis. 1996;22 Suppl 2:S128-S132.

28. Rongioletti F, et al. Proximal white subungual onychomycosis: a sign of immunodeficiency. J Am Acad Dermatol. 1994;30:129-130.

29. Arzeni D, et al. In vitro activity of terbinafine against clinical isolates of dermatophytes. Med Mycol. 1998; 36:235-237.

30. Villars VV, Jones TC. Special featuresof the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol. 1992;126 suppl 34; 61-9.

31. Herranz P, et al. Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine. Br J Dermatol. 1997;137:577-580.

32. Nandwani R, et al. Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis. Br J Dermatol. 1996;134 Suppl 46:22-24.

33. Albreski DA, Gross EG. The safety of itraconazole in the diabetic population. J Am Podiatr Med Assoc. 1999;89:339-345.

34. Albreski DA, et al. Onychomycosis in diabetes. Management considerations. Postgrad Med. 1999;Spec No:26-30.

35. Gupta AK, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol. 1998;139:665-671.

36. Rich P. Onychomycosis and tinea pedis in patients with diabetes. J Am Acad Dermatol. 2000;43:S130-S134.

37. Levy LA. Epidemiology of onychomycosis in special-risk populations. J Am Podiatr Med Assoc. 1997;87:546-550.

38. Anarella JJ, et al. Preventing complications in the diabetic patient with toenail onychomycosis. J Am Podiatr Med Assoc. 2001;91:325-328.

39. Farkas B, et al. Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial. Br J Dermatol. 2002;146:254-260.

40. Gupta AK, Lambert J. Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA. Int J Dermatol. 1999;38 Suppl 2:53-64.